Benzinga · Feb 18, 2026
HI
NASDAQ · HIND
Vyome Holdings, Inc.
Healthcare · Biotechnology
$1.77
Down-$0.03 (-1.69%)
Updated Nov 4, 2026, 9:00 PM
SID Score
3.0/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 27.41M
- P/E ratio
- -0.12
- Dividend yield
- 0.00%
- 52-week range
- $1.62 – $6.56
- Volume
- 5.27K
- Avg. volume
- 321.94K
Price performance · HIND
HIND price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 3, 2026
HIND closed at $1.77 after 21 trading sessions, down 14.08% for the selected period.
- Last close
- $1.77
- Period change
- -14.08%
- Period low
- $1.70
- Period high
- $2.09
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 3, 2026 | $1.8063 | $1.84 | $1.77 | $1.77 | 5.27K |
| Nov 2, 2026 | $1.86 | $1.91 | $1.76 | $1.76 | 9.65K |
| Oct 30, 2026 | $1.73 | $2.14 | $1.7184 | $1.80 | 42.19K |
| Oct 29, 2026 | $1.72 | $1.8266 | $1.72 | $1.75 | 13.16K |
| Oct 28, 2026 | $1.68 | $1.72 | $1.6202 | $1.72 | 8.07K |
| Oct 27, 2026 | $1.71 | $1.75 | $1.688 | $1.70 | 5.03K |
| Oct 26, 2026 | $1.7818 | $1.87 | $1.7009 | $1.71 | 16.72K |
| Oct 23, 2026 | $1.7937 | $1.7937 | $1.775 | $1.79 | 2.25K |
| Oct 22, 2026 | $1.84 | $1.84 | $1.75 | $1.80 | 10.87K |
| Oct 21, 2026 | $1.86 | $1.87 | $1.84 | $1.84 | 2.24K |
| Oct 20, 2026 | $1.86 | $1.88 | $1.83 | $1.84 | 8.25K |
| Oct 19, 2026 | $1.87 | $1.87 | $1.84 | $1.84 | 8.95K |
| Oct 16, 2026 | $1.89 | $1.91 | $1.8601 | $1.87 | 11.24K |
| Oct 15, 2026 | $1.9179 | $1.9299 | $1.83 | $1.91 | 14.99K |
| Oct 14, 2026 | $1.94 | $1.9808 | $1.91 | $1.93 | 6.36K |
| Oct 13, 2026 | $2.09 | $2.09 | $1.95 | $1.97 | 9.96K |
| Oct 12, 2026 | $2.04 | $2.045 | $1.99 | $2.01 | 7.05K |
| Oct 9, 2026 | $2.03 | $2.09 | $2.01 | $2.09 | 7.59K |
| Oct 8, 2026 | $2.03 | $2.0301 | $1.98 | $2.03 | 8K |
| Oct 7, 2026 | $2.02 | $2.06 | $1.98 | $2.04 | 11.37K |
| Oct 6, 2026 | $2.01 | $2.07 | $1.9043 | $2.06 | 13.74K |
Latest HIND news
The latest Smart Investors Daily articles mentioning HIND.
Stock researchCompany · Overview
Company
Market Activity
Research & News
HIND research
Overview
Company profile and research snapshot.
Company profile
Vyome Holdings Inc is a reseach and development company. The Company operates in two segments, biotechnology and pharmaceutical products. The biotechnology segment comprises of operations around VT-1953, VT-1908, and VB-1953 programs that are in development, and the pharmaceutical segment comprises of antifungal products manufacturing and distribution.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $15.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 3, 2026 | Chardan Capital | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Feb 11, 2026
Vyome Files For Orphan Drug Status For VT-1953, Its Lead Clinical Program
Acceptance of Orphan Drug Status would confer certain anticipated US Market Exclusivity, R&D tax benefits, and PDUFA fee waiver of approximately $3MIndependent third-party assessment estimates a current VT-1953
Benzinga · Feb 4, 2026
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga · Feb 2, 2026
Vyome Capitalizes VT-1953 Phase 3 Interim Results By Raising $5.29M Through Sale Of 1,089,045 Shares At $5.00
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
